Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 603

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma

Open access
Sullivan, Keith M., Goldmuntz, Ellen A., Keyes-Elstein, Lynette, McSweeney, Peter A., Pinckney, Ashley, Welch, Beverly, Mayes, Maureen D., Nash, Richard A., Crofford, Leslie J., Eggleston, Barry, Castina, Sharon, Griffith, Linda M., Goldstein, Julia S., Wallace, Dennis, Craciunescu, Oana, Khanna, Dinesh, Folz, Rodney J., Goldin, Jonathan, St. Clair, E. William, Seibold, James R., Phillips, Kristine, Mineishi, Shin, Simms, Robert W., Ballen, Karen, Wener, Mark H., Georges, George E., Heimfeld, Shelly, Hosing, Chitra, Forman, Stephen, Kafaja, Suzanne, Silver, Richard M., Griffing, Leroy, Storek, Jan, LeClercq, Sharon, Brasington, Richard, Csuka, Mary E., Bredeson, Christopher, Keever-Taylor, Carolyn, Domsic, Robyn T., Kahaleh, M. Bashar, Medsger, Thomas, Furst, Daniel E.·2018·New England Journal of Medicine

Abstract

BACKGROUND: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly infusions of cyclophosphamide in patients with scleroderma. METHODS: We randomly assigned adults (18 to 69 years of age) with severe scleroderma to undergo myeloablative autologous stem-cell transplantation (36 participants) or to receive cyclophosphamide (39 participants). The primary end point was a global rank composite score comparing participants with each other on the basis of a hierarchy of disease features assessed at 54 months: death, event-free survival (survival without respiratory, renal, or cardiac failure), forced vital capacity, the score on the Disability Index of the Health Assessment Questionnaire, and the modified Rodnan skin score. RESULTS: In the intention-to-treat population, global rank composite scores at 54 months showed the superiority of transplantation (67% of 1404 pairwise comparisons favored transplantation and 33% favored cyclophosphamide, P=0.01). In the per-protocol population (participants who received a transplant or completed ≥9 doses of cyclophosphamide), the rate of event-free survival at 54 months was 79% in the transplantation group and 50% in the cyclophosphamide group (P=0.02). At 72 months, Kaplan-Meier estimates of event-free survival (74% vs. 47%) and overall survival (86% vs. 51%) also favored transplantation (P=0.03 and 0.02, respectively). A total of 9% of the participants in the transplantation group had initiated disease-modifying antirheumatic drugs (DMARDs) by 54 months, as compared with 44% of those in the cyclophosphamide group (P=0.001). Treatment-related mortality in the transplantation group was 3% at 54 months and 6% at 72 months, as compared with 0% in the cyclophosphamide group. CONCLUSIONS: Myeloablative autologous hematopoietic stem-cell transplantation achieved long-term benefits in patients with scleroderma, including improved event-free and overall survival, at a cost of increased expected toxicity. Rates of treatment-related death and post-transplantation use of DMARDs were lower than those in previous reports of nonmyeloablative transplantation. (Funded by the National Institute of Allergy and Infectious Diseases and the National Institutes of Health; ClinicalTrials.gov number, NCT00114530 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1703327

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 603

Metadata

Authors
Sullivan, K. M., Goldmuntz, E. A., Keyes-Elstein, L., McSweeney, P. A., Pinckney, A., Welch, B., Mayes, M. D., Nash, R. A., Crofford, L. J., Eggleston, B., Castina, S., Griffith, L. M., Goldstein, J. S., Wallace, D., Craciunescu, O., Khanna, D., Folz, R. J., Goldin, J., St. Clair, E. W., Seibold, J. R., Phillips, K., Mineishi, S., Simms, R. W., Ballen, K., Wener, M. H., Georges, G. E., Heimfeld, S., Hosing, C., Forman, S., Kafaja, S., Silver, R. M., Griffing, L., Storek, J., LeClercq, S., Brasington, R., Csuka, M. E., Bredeson, C., Keever-Taylor, C., Domsic, R. T., Kahaleh, M. B., Medsger, T., & Furst, D. E.
Venue
New England Journal of Medicine
Published
2018-01-04
Volume
378
Issue
1
Pages
35-47
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2782208928
Cited by
603
References
32
FWCI
47.41
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. https://app.cochat.ai/papers/10.1056/nejmoa1703327
The paper
Sullivan, K. M., Goldmuntz, E. A., Keyes-Elstein, L., McSweeney, P. A., Pinckney, A., Welch, B., Mayes, M. D., Nash, R. A., Crofford, L. J., Eggleston, B., Castina, S., Griffith, L. M., Goldstein, J. S., Wallace, D., Craciunescu, O., Khanna, D., Folz, R. J., Goldin, J., St. Clair, E. W., . . . Furst, D. E. (2018). Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1703327

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.